J&J pledges to end global TB pandemic
pharmafile | September 25, 2018 | News story | Manufacturing and Production | J&J, JJ, Johnson and Johnson, TB, access, tuberculosis
Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s most deadly infectious disease.
Through efforts to improve detection, broaden access to treatments, and accelerate R&D, the American pharma firm hope to save 1.8 million lives while preventing 12 million new TB infections, over the next ten years.
“TB is the world’s number one infectious killer, and TB and MDR-TB cause major devastation for people, communities and entire countries around the world,” Dr Paul Stoffels , Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson, said in a statement. “The good news is TB is both preventable and treatable, and Johnson & Johnson is committed to doing everything we can to create a world free from TB. This new initiative will unleash the power of science and technology to forever change the trajectory of TB.”
While 10 million people fall ill with tuberculosis each year approximately 1.6 million die. However current treatments have particularly low cure rates and can equally lead to debilitating and even fatal side effects. The disease is also developing resistance to first line medicines as drug resistant TB now accounts for approximately one third of AMR related deaths.
As such, Jaak Peeters, Global Head, Johnson & Johnson Global Public Health, Janssen-Cilag GmbH, commented: “Our goal is to end the TB epidemic forever by finding and treating patients all over the world.”
Louis Goss
Related Content
M42 study highlights positive performance of AI model for tuberculosis screening
Healthcare tech company, M42, has published results from one of the largest real-world studies of …
J&J seek approval for first drug to treat high-risk smoldering myeloma
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …
